$REPL up 24% 🚀 🔹 Replimune rebounding hard as biotech traders jump back into the name 📈 🔹 Company is developing oncolytic immunotherapies designed to trigge

$REPL up 24% 🚀 🔹 Replimune rebounding hard as biotech traders jump back into the name 📈 🔹 Company is developing oncolytic immunotherapies designed to trigger anti-tumor immune responses 🧬 🔹 Main focus remains RP1 in advanced melanoma, in combination with Bristol Myers’ Opdivo 🔥 🔹 Stock has b…